What's new

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised

Mar 17, 2025 - 17:11
 0
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Skilarence, dimethyl f...

Next Article

Expo West: Plant Press Pushes Forward, Humm Flexes Formats

Related Posts

Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Date of authorisation: 24/08/2017, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 13, 2025  0

Veterinary medicines European public assessment report (EPAR): Mhyosphere PCV ID, Mycoplasma hyopneumoniae and porcine circovirus vaccine (inactivated, recombinant), Status: Authorised

Veterinary medicines European public assessment report ...

Mar 14, 2025  0

Orphan designation: (R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)pyrrolidin-1-yl)(5-hydroxy-6-methylpyridin-2-yl)methanone Treatment of Olmsted syndrome, 26/02/2025 Positive

Orphan designation: (R)-(3-(2'-cyclopropyl-3-(hydr...

Mar 11, 2025  0